Treatment of COVID-19 patients using plasma therapy: Letter to Editor
The symptoms of COVID-19, caused by the newly known type of coronavirus, vary widely from asymptomatic, mild to severe respiratory infection leading to hospitalization or death of patients. To date, no specific drug has been reported for the treatment of patients affected by this virus. One of the approaches adopted for the treatment of this disease is the use of plasma therapy, which contains antibodies against the virus. Following of the plasma therapy have not been reported any serious side effects. Currently, the numbers of these studies are limited, and evaluation of the larger population studies can provide stronger evidence for treating physicians about the effectiveness of this therapeutic approach..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
مجله دانشگاه علوم پزشکی بیرجند - 28(2021), 1, Seite 84-87 |
| Sprache: |
Persisch |
|---|
| Beteiligte Personen: |
Nafiseh Erfanian [VerfasserIn] |
|---|
| Links: |
doaj.org [kostenfrei] |
|---|
| Themen: |
Covid-19 patient |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
DOAJ022438513 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ022438513 | ||
| 003 | DE-627 | ||
| 005 | 20230307055256.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2021 xx |||||o 00| ||per c | ||
| 035 | |a (DE-627)DOAJ022438513 | ||
| 035 | |a (DE-599)DOAJf6d4893ac1ef41ce939189c2e0a25153 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a per | ||
| 050 | 0 | |a R5-920 | |
| 100 | 0 | |a Nafiseh Erfanian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of COVID-19 patients using plasma therapy: Letter to Editor |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The symptoms of COVID-19, caused by the newly known type of coronavirus, vary widely from asymptomatic, mild to severe respiratory infection leading to hospitalization or death of patients. To date, no specific drug has been reported for the treatment of patients affected by this virus. One of the approaches adopted for the treatment of this disease is the use of plasma therapy, which contains antibodies against the virus. Following of the plasma therapy have not been reported any serious side effects. Currently, the numbers of these studies are limited, and evaluation of the larger population studies can provide stronger evidence for treating physicians about the effectiveness of this therapeutic approach. | ||
| 650 | 4 | |a covid-19 patient | |
| 650 | 4 | |a plasma therapy | |
| 650 | 4 | |a virus | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Medicine (General) | |
| 700 | 0 | |a Ebrahim Miri-Moghaddam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t مجله دانشگاه علوم پزشکی بیرجند |d Birjand University of Medical Sciences and Health Services, 2016 |g 28(2021), 1, Seite 84-87 |w (DE-627)DOAJ000136220 |x 24236152 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2021 |g number:1 |g pages:84-87 |
| 856 | 4 | 0 | |u https://doaj.org/article/f6d4893ac1ef41ce939189c2e0a25153 |z kostenfrei |
| 856 | 4 | 0 | |u http://journal.bums.ac.ir/article-1-2929-en.html |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1607-2197 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2423-6152 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2021 |e 1 |h 84-87 | ||